The deal, worth up to $400m, will see the companies develop an early-stage alpha-synuclein antibody, a hot area of research in Parkinson's disease.
AstraZeneca PLC is continuing its strategy of partnering some of its promising but not core compounds by inking a deal with Takeda Pharmaceutical Co. Ltd. to develop an alpha-synuclein antibody as a potentially disease-modifying treatment for Parkinson’s disease.
Under the terms of the agreement, AstraZeneca will take the drug, codenamed MEDI1341, through Phase I, while Takeda will lead future clinical development activities
Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.
PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.
Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.
